1. Home
  2. LPTX vs IDR Comparison

LPTX vs IDR Comparison

Compare LPTX & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • IDR
  • Stock Information
  • Founded
  • LPTX 2011
  • IDR 1996
  • Country
  • LPTX United States
  • IDR United States
  • Employees
  • LPTX N/A
  • IDR N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • IDR Precious Metals
  • Sector
  • LPTX Health Care
  • IDR Basic Materials
  • Exchange
  • LPTX Nasdaq
  • IDR Nasdaq
  • Market Cap
  • LPTX 119.6M
  • IDR 142.7M
  • IPO Year
  • LPTX N/A
  • IDR N/A
  • Fundamental
  • Price
  • LPTX $0.48
  • IDR $12.66
  • Analyst Decision
  • LPTX Buy
  • IDR Strong Buy
  • Analyst Count
  • LPTX 3
  • IDR 1
  • Target Price
  • LPTX $8.50
  • IDR $14.00
  • AVG Volume (30 Days)
  • LPTX 1.5M
  • IDR 177.8K
  • Earning Date
  • LPTX 03-17-2025
  • IDR 03-24-2025
  • Dividend Yield
  • LPTX N/A
  • IDR N/A
  • EPS Growth
  • LPTX N/A
  • IDR 344.27
  • EPS
  • LPTX N/A
  • IDR 0.52
  • Revenue
  • LPTX N/A
  • IDR $21,955,008.00
  • Revenue This Year
  • LPTX N/A
  • IDR $86.37
  • Revenue Next Year
  • LPTX N/A
  • IDR $11.11
  • P/E Ratio
  • LPTX N/A
  • IDR $25.24
  • Revenue Growth
  • LPTX N/A
  • IDR 64.93
  • 52 Week Low
  • LPTX $0.47
  • IDR $6.91
  • 52 Week High
  • LPTX $4.79
  • IDR $18.35
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 19.00
  • IDR 48.80
  • Support Level
  • LPTX $0.47
  • IDR $12.82
  • Resistance Level
  • LPTX $0.53
  • IDR $13.45
  • Average True Range (ATR)
  • LPTX 0.04
  • IDR 0.67
  • MACD
  • LPTX 0.07
  • IDR -0.13
  • Stochastic Oscillator
  • LPTX 7.42
  • IDR 1.08

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.

Share on Social Networks: